Pliant Therapeutics has reported interim results from its ongoing Phase I dose escalation trial of PLN-101095, along with pembrolizumab in patients with solid tumours. The drug evaluation is intended ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results